Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).
Balaña C, López-Pousa A, Berrocal A, Yaya-Tur R, Herrero A, García JL, Martín-Broto J, Benavides M, Cerdá-Nicolás M, Ballester R, Balart J, Capellades J. Balaña C, et al. Among authors: benavides m. J Neurooncol. 2004 Dec;70(3):359-69. doi: 10.1007/s11060-004-9175-1. J Neurooncol. 2004. PMID: 15662978 Clinical Trial.
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Gil MJ, de Las Peñas R, Reynés G, Balañá C, Peréz-Segura P, García-Velasco A, Mesia C, Gallego O, Fernández-Chacón C, Martínez-García M, Herrero A, Andrés R, Benavides M, Quintanar T, Pérez-Martin X. Gil MJ, et al. Among authors: benavides m. Anticancer Drugs. 2012 Jul;23(6):659-65. doi: 10.1097/CAD.0b013e3283534d3e. Anticancer Drugs. 2012. PMID: 22634799
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
Balañá C, Vaz MA, Lopez D, de la Peñas R, García-Bueno JM, Molina-Garrido MJ, Sepúlveda JM, Cano JM, Bugés C, Sanz SM, Arranz JL, Perez-Segura P, Rodriguez A, Martin JM, Benavides M, Gil M. Balañá C, et al. Among authors: benavides m. Clin Transl Oncol. 2014 Mar;16(3):273-9. doi: 10.1007/s12094-013-1068-3. Epub 2013 Jun 21. Clin Transl Oncol. 2014. PMID: 23793813
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.
Gallego O, Cuatrecasas M, Benavides M, Segura PP, Berrocal A, Erill N, Colomer A, Quintana MJ, Balaña C, Gil M, Gallardo A, Murata P, Barnadas A. Gallego O, et al. Among authors: benavides m. J Neurooncol. 2014 Jan;116(2):413-9. doi: 10.1007/s11060-013-1316-y. Epub 2013 Dec 19. J Neurooncol. 2014. PMID: 24352766 Free PMC article.
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A. Sepúlveda-Sánchez JM, et al. Among authors: benavides m. Neuro Oncol. 2017 Oct 19;19(11):1522-1531. doi: 10.1093/neuonc/nox105. Neuro Oncol. 2017. PMID: 28575464 Free PMC article. Clinical Trial.
SEOM clinical guidelines for anaplastic gliomas (2017).
Balañá C, Alonso M, Hernandez-Lain A, Hernandez A, Perez-Segura P, Pineda E, Ramos A, Sanchez AR, Teixidor P, Verger E, Benavides M. Balañá C, et al. Among authors: benavides m. Clin Transl Oncol. 2018 Jan;20(1):16-21. doi: 10.1007/s12094-017-1762-7. Epub 2017 Oct 20. Clin Transl Oncol. 2018. PMID: 29058264 Free PMC article.
Correction to: SEOM clinical guidelines for anaplastic gliomas (2017).
Balañá C, Alonso M, Hernandez-Lain A, Perez-Segura P, Pineda E, Ramos A, Sanchez AR, Teixidor P, Verger E, Benavides M. Balañá C, et al. Among authors: benavides m. Clin Transl Oncol. 2018 Jul;20(7):937. doi: 10.1007/s12094-018-1904-6. Clin Transl Oncol. 2018. PMID: 29858734 Free PMC article.
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.
Pérez-Gracia JL, Colomer R, Esteban E, Barceló R, Benavides M, Puertas J, Arcediano A, Tornamira MV, Valentín V, Muñoz A, Cortés-Funes H, Hornedo J. Pérez-Gracia JL, et al. Among authors: benavides m. Cancer. 2001 Nov 15;92(10):2508-16. doi: 10.1002/1097-0142(20011115)92:10<2508::aid-cncr1601>3.0.co;2-#. Cancer. 2001. PMID: 11745183 Clinical Trial.
273 results